Skip to main content
SpringerLink
Log in

Avoiding PXR and CAR Activation and CYP3A4 Enzyme Induction

  • Chapter
  • First Online:
Book cover Tactics in Contemporary Drug Design

Part of the book series: Topics in Medicinal Chemistry ((TMC,volume 9))

Abstract

Avoiding drug–drug interactions is an important aspect of today’s drug discovery and development process. The most significant of these interactions occur through changes in the enzyme level of CYP3A4 which is involved in the metabolism of many drugs. Increases in the expression of CYP3A4 mRNA and enzyme activity can occur through several mechanisms, the most predominant of which is the activation of transcription factors, such as the nuclear hormone receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR). Through an understanding of interactions between drugs (ligands) and the ligand binding pockets of these receptors, several laboratories have attenuated the binding interactions and significantly reduced the potential for CYP3A4 induction and ultimately drug–drug interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Huang SM, Lesko LJ (2004) Drug–drug, drug–dietary supplement, and drug–citrus fruit and other food interactions: what have we learned? J Clin Pharmacol 44:559–569

    Article  CAS  Google Scholar 

  2. Huang SM, Strong JM, Zhang L et al (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662–670

    Article  CAS  Google Scholar 

  3. Muirhead GJ, Wulff MB, Fielding A et al (2000) Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 50:99–107

    Article  CAS  Google Scholar 

  4. Obach RS, Ryder TF (2010) Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos 38:1381–1391

    Article  CAS  Google Scholar 

  5. Backman JT, Olkkola KT, Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7–13

    Article  CAS  Google Scholar 

  6. Backman JT, Olkkola KT, Ojala M et al (1996) Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 37:253–257

    Article  CAS  Google Scholar 

  7. Ma JD, Nafziger AN, Rhodes G et al (2006) Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab Dispos 34:783–785

    Article  CAS  Google Scholar 

  8. Levy R (2012) Metabolism and transport drug–drug interaction database, 2005–2012 edn. University of Washington, Washington

    Google Scholar 

  9. Chang TK (2009) Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J 11:590–601

    Article  CAS  Google Scholar 

  10. Choi SY, Koh KH, Jeong H (2013) Isoform-specific regulation of cytochromes p450 expression by estradiol and progesterone. Drug Metab Dispos 41:263–269

    Article  CAS  Google Scholar 

  11. Jeong H, Choi S, Song JW et al (2008) Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica 38:62–75

    Article  CAS  Google Scholar 

  12. Bertilsson L, Hojer B, Tybring G et al (1980) Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther 27:83–88

    Article  CAS  Google Scholar 

  13. Simonsson US, Jansson B, Hai TN et al (2003) Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 74:32–43

    Article  CAS  Google Scholar 

  14. Wilkinson GR (2001) Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman J, Limbird L, Goodman Gilman A (eds) The pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York

    Google Scholar 

  15. Ema (2012) Guideline on the investigation of drug interactions. Guideline on the investigation of drug interactions [Online]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf Accessed September 2012

  16. FDA (2012) Guidance for industry: drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. Guidance for industry: drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations [Online]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf

  17. Kumar S, Sharma R, Roychowdhury A (2012) Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective. Curr Med Chem 19:3605–3621

    Article  CAS  Google Scholar 

  18. Pascussi JM, Drocourt L, Gerbal-Chaloin S et al (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268:6346–6358

    Article  CAS  Google Scholar 

  19. Li L, Sinz MW, Zimmermann K et al (2012) An insulin-like growth factor 1 receptor inhibitor induces CYP3A4 expression through a pregnane X receptor-independent, noncanonical constitutive androstane receptor-related mechanism. J Pharmacol Exp Ther 340:688–697

    Article  CAS  Google Scholar 

  20. Gonzalez FJ (2007) The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab Dispos 35:1–8

    Article  CAS  Google Scholar 

  21. Timsit YE, Negishi M (2007) CAR and PXR: the xenobiotic-sensing receptors. Steroids 72:231–246

    Article  CAS  Google Scholar 

  22. Shukla SJ, Nguyen DT, Macarthur R et al (2009) Identification of pregnane X receptor ligands using time-resolved fluorescence resonance energy transfer and quantitative high-throughput screening. Assay Drug Dev Technol 7:143–169

    Article  CAS  Google Scholar 

  23. Shukla SJ, Sakamuru S, Huang R et al (2011) Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos 39:151–159

    Article  CAS  Google Scholar 

  24. Sinz M, Kim S, Zhu Z et al (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375–388

    Article  CAS  Google Scholar 

  25. Di Masi A, De Marinis E, Ascenzi P et al (2009) Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects. Mol Aspects Med 30:297–343

    Article  Google Scholar 

  26. Poso A, Honkakoski P (2006) Ligand recognition by drug-activated nuclear receptors PXR and CAR: structural, site-directed mutagenesis and molecular modeling studies. Mini Rev Med Chem 6:937–947

    Article  CAS  Google Scholar 

  27. Jones SA, Moore LB, Shenk JL et al (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27–39

    Article  CAS  Google Scholar 

  28. Kim S, Dinchuk JE, Anthony MN et al (2010) Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction. Drug Metab Dispos 38:16–24

    Article  CAS  Google Scholar 

  29. Kliewer SA, Goodwin B, Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687–702

    Article  CAS  Google Scholar 

  30. Nishimura M, Koeda A, Suganuma Y et al (2007) Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. Drug Metab Pharmacokinet 22:178–186

    Article  CAS  Google Scholar 

  31. Prueksaritanont T, Kuo Y, Tang C et al (2006) In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos 34:1546–1555

    Article  CAS  Google Scholar 

  32. Carnahan VE, Redinbo MR (2005) Structure and function of the human nuclear xenobiotic receptor PXR. Curr Drug Metab 6:357–367

    Article  CAS  Google Scholar 

  33. Chen T (2008) Nuclear receptor drug discovery. Curr Opin Chem Biol 12:418–426

    Article  CAS  Google Scholar 

  34. Chen Y, Tang Y, Robbins GT et al (2010) Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. J Pharmacol Exp Ther 334:999–1008

    Article  CAS  Google Scholar 

  35. Huang H, Wang H, Sinz M et al (2007) Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26:258–268

    Article  Google Scholar 

  36. Lim YP, Ma CY, Liu CL et al (2012) Sesamin: a naturally occurring lignan inhibits CYP3A4 by antagonizing the pregnane X receptor activation. Evid Based Complement Alternat Med 2012:242810

    Google Scholar 

  37. Mcginnity DF, Zhang G, Kenny JR et al (2009) Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 37:1259–1268

    Article  CAS  Google Scholar 

  38. Raucy JL, Lasker JM (2010) Current in vitro high throughput screening approaches to assess nuclear receptor activation. Curr Drug Metab 11:806–814

    Article  CAS  Google Scholar 

  39. Sinz M, Wallace G, Sahi J (2008) Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 10:391–400

    Article  CAS  Google Scholar 

  40. Zhu Z, Kim S, Chen T et al (2004) Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 9:533–540

    Article  CAS  Google Scholar 

  41. Zhu Z, Puglisi J, Connors D et al (2007) Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assay. J Biomol Screen 12:248–254

    Article  CAS  Google Scholar 

  42. Cui X, Thomas A, Gerlach V et al (2008) Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers. Biochem Pharmacol 76:680–689

    Article  CAS  Google Scholar 

  43. El-Sankary W, Gibson GG, Ayrton A et al (2001) Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 29:1499–1504

    CAS  Google Scholar 

  44. Chu V, Einolf HJ, Evers R et al (2009) In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective. Drug Metab Dispos 37:1339–1354

    Article  CAS  Google Scholar 

  45. Fahmi OA, Ripp SL (2010) Evaluation of models for predicting drug–drug interactions due to induction. Expert Opin Drug Metab Toxicol 6:1399–1416

    Article  CAS  Google Scholar 

  46. Hewitt NJ, De Kanter R, Lecluyse E (2007) Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry–do they comply with FDA recommendations? Chem Biol Interact 168:51–65

    Article  CAS  Google Scholar 

  47. Sinz M, Kim S (2006) Stem cells, immortalized cells, and primary cells in ADMET assays. Drug Discov Today Technol 3:79–85

    Article  Google Scholar 

  48. Hasegawa M, Kapelyukh Y, Tahara H et al (2011) Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol 80:518–528

    Article  CAS  Google Scholar 

  49. Kim S, Pray D, Zheng M et al (2008) Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: extrapolation to human CYP3A4 induction potential. Drug Metab Lett 2:169–175

    Article  CAS  Google Scholar 

  50. Gao YD, Olson SH, Balkovec JM et al (2007) Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach. Xenobiotica 37:124–138

    Article  CAS  Google Scholar 

  51. Schuster D, Langer T (2005) The identification of ligand features essential for PXR activation by pharmacophore modeling. J Chem Inf Model 45:431–439

    Article  CAS  Google Scholar 

  52. Schlegel KA, Yang ZQ, Reger TS et al (2010) Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists. Bioorg Med Chem Lett 20:5147–5152

    Article  CAS  Google Scholar 

  53. Harper S, Avolio S, Pacini B et al (2005) Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J Med Chem 48:4547–4557

    Article  CAS  Google Scholar 

  54. Fotsch C, Bartberger MD, Bercot EA et al (2008) Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model. J Med Chem 51:7953–7967

    Article  CAS  Google Scholar 

  55. Rew Y, Mcminn DL, Wang Z et al (2009) Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11beta-HSD1 inhibitors. Bioorg Med Chem Lett 19:1797–1801

    Article  CAS  Google Scholar 

  56. Kaizerman JA, Aaron W, An S et al (2010) Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines. Bioorg Med Chem Lett 20:4607–4610

    Article  CAS  Google Scholar 

  57. Zimmermann K, Wittman MD, Saulnier MG et al (2010) SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. Bioorg Med Chem Lett 20:1744–1748

    Article  CAS  Google Scholar 

  58. Khandelwal A, Krasowski MD, Reschly EJ et al (2008) Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol 21:1457–1467

    Article  CAS  Google Scholar 

  59. Wipf P, Gong H, Janjic JM et al (2007) New opportunities for pregnane X receptor (PXR) targeting in drug development. lessons from Enantio- and species-specific PXR ligands identified from a discovery library of amino acid analogues. Mini Rev Med Chem 7:617–625

    Article  CAS  Google Scholar 

  60. Wang H, Lecluyse EL (2003) Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 42:1331–1357

    Article  CAS  Google Scholar 

  61. Lynch C, Pan Y, Li L et al (2012) Identification of novel activators of constitutive androstane receptor from FDA-approved drugs by integrated computational and biological approaches. Pharm Res 30:489–501

    Article  Google Scholar 

  62. Zhou X, Xu H (2009) Structure and function of PXR and CAR. In: Xie W (ed) Nuclear receptors in drug metabolism. Wiley, Hoboken

    Google Scholar 

  63. Xu RX, Lambert MH, Wisely BB et al (2004) A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Mol Cell 16:919–928

    Article  CAS  Google Scholar 

  64. Kachaylo EM, Pustylnyak VO, Lyakhovich VV et al (2011) Constitutive androstane receptor (CAR) is a xenosensor and target for therapy. Biochemistry (Mosc) 76:1087–1097

    Article  CAS  Google Scholar 

  65. Anderson LE, Dring AM, Hamel LD et al (2011) Modulation of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) by 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives, ligands of peripheral benzodiazepine receptor (PBR). Toxicol Lett 202:148–154

    Article  CAS  Google Scholar 

  66. Kublbeck J, Jyrkkarinne J, Molnar F et al (2011) New in vitro tools to study human constitutive androstane receptor (CAR) biology: discovery and comparison of human CAR inverse agonists. Mol Pharm 8:2424–2433

    Article  CAS  Google Scholar 

  67. Faucette SR, Zhang TC, Moore R et al (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72–80

    Article  CAS  Google Scholar 

  68. Kanno Y, Inouye Y (2010) A consecutive three alanine residue insertion mutant of human CAR: a novel CAR ligand screening system in HepG2 cells. J Toxicol Sci 35:515–525

    Article  CAS  Google Scholar 

  69. Kublbeck J, Laitinen T, Jyrkkarinne J et al (2011) Use of comprehensive screening methods to detect selective human CAR activators. Biochem Pharmacol 82:1994–2007

    Article  Google Scholar 

  70. Pascussi JM, Gerbal-Chaloin S, Duret C et al (2008) The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol 48:1–32

    Article  CAS  Google Scholar 

  71. Li H, Chen T, Cottrell J et al (2009) Nuclear translocation of adenoviral-enhanced yellow fluorescent protein-tagged-human constitutive androstane receptor (hCAR): a novel tool for screening hCAR activators in human primary hepatocytes. Drug Metab Dispos 37:1098–1106

    Article  CAS  Google Scholar 

  72. Wu B, Li S, Dong D (2013) 3D structure and ligand specificity of nuclear xenobiotic receptors CAR, PXR and VDR. Drug Discov Today 18:574–581

    Article  CAS  Google Scholar 

  73. Pustylnyak V, Yarushkin A, Kachaylo E et al (2011) Effect of several analogs of 2,4,6-triphenyldioxane-1,3 on constitutive androstane receptor activation. Chem Biol Interact 192:177–183

    Article  CAS  Google Scholar 

  74. Repo S, Jyrkkarinne J, Pulkkinen JT et al (2008) Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis. J Med Chem 51:7119–7131

    Article  CAS  Google Scholar 

  75. Dring AM, Anderson LE, Qamar S et al (2010) Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact 188:512–525

    Article  CAS  Google Scholar 

  76. Kublbeck J, Jyrkkarinne J, Poso A et al (2008) Discovery of substituted sulfonamides and thiazolidin-4-one derivatives as agonists of human constitutive androstane receptor. Biochem Pharmacol 76:1288–1297

    Article  CAS  Google Scholar 

  77. Jyrkkarinne J, Windshugel B, Ronkko T et al (2008) Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship. J Med Chem 51:7181–7192

    Article  Google Scholar 

  78. Kohle C, Bock KW (2009) Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 77:689–699

    Article  Google Scholar 

  79. Li H, Wang H (2010) Activation of xenobiotic receptors: driving into the nucleus. Expert Opin Drug Metab Toxicol 6:409–426

    Article  CAS  Google Scholar 

  80. Pavek P, Dvorak Z (2008) Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 9:129–143

    Article  CAS  Google Scholar 

  81. Tolson AH, Wang H (2010) Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 62:1238–1249

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bristol Myers-Squibb Research and Development, 5 Research Parkway, Wallingford, CT, 06492, USA

    Michael W. Sinz

Authors
  1. Michael W. Sinz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael W. Sinz .

Editor information

Editors and Affiliations

  1. Bristol-Myers Squibb, Wallingford, Connecticut, USA

    Nicholas A. Meanwell

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Sinz, M.W. (2013). Avoiding PXR and CAR Activation and CYP3A4 Enzyme Induction. In: Meanwell, N. (eds) Tactics in Contemporary Drug Design. Topics in Medicinal Chemistry, vol 9. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7355_2013_24

Download citation

Publish with us

Policies and ethics

Search

Navigation